Evaluation of Lipids, Drug Concentration, and Safety Parameters Following Cessation of Treatment With the Cholesteryl Ester Transfer Protein Inhibitor Anacetrapib in Patients With or at High Risk for Coronary Heart Disease
Gotto, Antonio M., MD, DPhil, Cannon, Christopher P., MD, Li, Xiujiang Susie, PhD, Vaidya, Sanskruti, MS, MPhil, Kher, Uma, MS, Brinton, Eliot A., MD, Davidson, Michael, MD, Moon, Jennifer E., PhD, Shah, Sukrut, PhD, RPh, Dansky, Hayes M., MD, Mitchel, Yale, MD, Barter, Philip, MD, PhD
Published in The American journal of cardiology (2014)
Published in The American journal of cardiology (2014)
Get full text
Journal Article
Lipid-modifying Efficacy and Tolerability of Anacetrapib Added to Ongoing Statin Therapy in Patients With Hypercholesterolemia or Low High-density Lipoprotein Cholesterol
Ballantyne, Christie M., MD, Shah, Sukrut, PhD, Kher, Uma, MS, Hunter, John A., MS, Gill, Geraldine G., MPharm, Cressman, Michael D., DO, Ashraf, Tanya B., BA, Johnson-Levonas, Amy O., PhD, Mitchel, Yale B., MD
Published in The American journal of cardiology (01.02.2017)
Published in The American journal of cardiology (01.02.2017)
Get full text
Journal Article